Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29859951 | 0.89 | CHRM1 (0.42) | CYP11B1CYP11B2CHRM1CHRM4CHRM2 | |
| SCHEMBL20942447 | 0.89 | CHRM1 (0.42) | CYP11B1CYP11B2CHRM1CHRM4CHRM2 | |
| SCHEMBL20942069 | 0.89 | CHRM1 (0.42) | CYP11B1CYP11B2CHRM1CHRM4CHRM2 | |
| SCHEMBL17101289 | 0.89 | CHRM1 (0.42) | CYP11B1CYP11B2CHRM1CHRM4CHRM2 | |
| SCHEMBL22472925 | 0.88 | CYP11B1 (0.34) | CYP11B1CYP11B2LRRK2 | |
| SCHEMBL17101370 | 0.87 | CHRM1 (0.40) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| SCHEMBL22449310 | 0.86 | CHRM1 (0.34) | CYP11B1CYP11B2CHRM1CHRM4CHRM2 | |
| SCHEMBL17101337 | 0.85 | CHRM1 (0.43) | CYP11B1CYP11B2CHRM1CHRM4CHRM2 | |
| SCHEMBL21597915 | 0.84 | CHRM1 (0.33) | CYP11B1CYP11B2CHRM1CHRM4CHRM2 | |
| SCHEMBL22472873 | 0.83 | CHRM1 (0.39) | CHRM1CHRM4MAPK1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | CYP11B1 412/4885CYP11B2 468/4885CHRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.